Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Jende JME, Groener JB, Rother C, et al. Association of Serum Cholesterol Levels With Peripheral Nerve Damage in Patients With Type 2 Diabetes. JAMA Netw Open. 2019;2(5):e194798. doi:10.1001/jamanetworkopen.2019.4798
Is there an association between a low serum cholesterol level and the extent of peripheral nerve damage as assessed with magnetic resonance neurography in patients with type 2 diabetes?
In this cross-sectional cohort study of 100 adults with type 2 diabetes, the amount of nerve lesions was negatively associated with total serum cholesterol levels.
The findings suggest that lowering serum cholesterol levels in patients with type 2 diabetes is associated with diabetic polyneuropathy.
Lowering serum cholesterol levels is a well-established treatment for dyslipidemia in patients with type 2 diabetes (T2D). However, nerve lesions in patients with T2D increase with lower serum cholesterol levels, suggesting that lowering serum cholesterol levels is associated with diabetic polyneuropathy (DPN) in patients with T2D.
To investigate whether there is an association between serum cholesterol levels and peripheral nerve lesions in patients with T2D with and without DPN.
Design, Setting, and Participants
This single-center, cross-sectional, prospective cohort study was performed from June 1, 2015, to March 31, 2018. Observers were blinded to clinical data. A total of 256 participants were approached, of whom 156 were excluded. A total of 100 participants consented to undergo magnetic resonance neurography of the right leg at the Department of Neuroradiology and clinical, serologic, and electrophysiologic assessment at the Department of Endocrinology, Heidelberg University Hospital, Heidelberg, Germany.
Quantification of the nerve’s diameter and lipid equivalent lesion (LEL) load with a subsequent analysis of all acquired clinical and serologic data with use of 3.0-T magnetic resonance neurography of the right leg with 3-dimensional reconstruction of the sciatic nerve.
Main Outcomes and Measures
The primary outcome was lesion load and extension. Secondary outcomes were clinical, serologic, and electrophysiologic findings.
A total of 100 participants with T2D (mean [SD] age, 64.6 [0.9] years; 68 [68.0%] male) participated in the study. The LEL load correlated positively with the nerve’s mean cross-sectional area (r = 0.44; P < .001) and the maximum length of a lesion (r = 0.71; P < .001). The LEL load was negatively associated with total serum cholesterol level (r = −0.41; P < .001), high-density lipoprotein cholesterol level (r = −0.30; P = .006), low-density lipoprotein cholesterol level (r = −0.33; P = .003), nerve conduction velocities of the tibial (r = −0.33; P = .01) and peroneal (r = −0.51; P < .001) nerves, and nerve conduction amplitudes of the tibial (r = −0.31; P = .02) and peroneal (r = −0.28; P = .03) nerves.
Conclusions and Relevance
The findings suggest that lowering serum cholesterol levels in patients with T2D and DPN is associated with a higher amount of nerve lesions and declining nerve conduction velocities and amplitudes. These findings may be relevant to emerging therapies that promote an aggressive lowering of serum cholesterol levels in patients with T2D.
Create a personal account or sign in to: